GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

In the face of "unprecedented" demand for its shingles vaccine, GlaxoSmithKline is doing everything it can to boost supply. But in spite of those efforts—it shipped as much vaccine in the third quarter as it did in the first half of the year—GSK says the Shingrix shortage will persist into 2019.